Johnson & Johnson(JNJ) - Stock detail

Johnson & Johnson

US
JNJ
Johnson & Johnson(Listing date: 09/25/1944)

Johnson & Johnson was incorporated in New Jersey in 1887. Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacturing and sale of various products in the healthcare field. Johnson & Johnson is a holding company, with its operating companies located in nearly all countries around the world. The company's primary focus is on products related to human health and well-being. The company is divided into two business segments: Innovative Medicine and MedTech.

AI Debate JudgeBuy
Generated at:2026-03-05 05:45:01
Data source: real-time quotes, news and fundamental analysis, analysis date: 2026-03-04
  • The forward P/E of 20.43 is a justified premium for a high-quality healthcare leader with 65-year dividend growth streak
  • The bullish thesis is forward-looking with concrete pipeline progress including FDA Fast Track for nipocalimab
  • Blockbuster success of Spravato provides tangible growth engines already offsetting Stelara decline
  • Technically, the stock is consolidating above all major moving averages in a clear bullish structure
  • Furthermore, the company is pivoting effectively and not just sitting still against known challenges
  • Most importantly, the known bearish risks are largely priced in and being actively managed
Bear Case
  • Elevated valuation after the recent run-up
  • Stelara patent cliff remains a significant concern
  • Talc litigation presents ongoing legal risks
  • Forward P/E of 20.43 represents premium valuation
  • Consolidation phase could indicate potential breakdown
  • Historical high stop-loss trigger rate of 50%
Bull Case
  • Robust pharmaceutical pipeline navigating patent cliff
  • FDA Fast Track designation for nipocalimab
  • Blockbuster success of Spravato providing growth
  • Defensive dividend aristocrat status in volatile markets
  • Technically sound bullish chart structure above moving averages
  • Potential value unlock from DePuy Synthes sale
  • High-margin pharmaceutical segments driving performance
  • Growth pipeline execution showing solid quarterly results
  • Neuroscience and immunology segments showing strong performance

Price Targets

Analysis Summary

Synthesizing the fundamental, technical, and news analyses, here are the specific price targets:

  • 1-Month Target (Conservative): $250 - $255
    • Rationale: A break above the near-term resistance at $248.81 to test the upper Bollinger Band/52-week high area. This is a momentum-driven move, factoring in the positive news flow.
  • 3-Month Target (Baseline): $260 - $265
    • Rationale: This aligns with the fundamental valuation from the reports, driven by continued execution on the growth pipeline and solid quarterly earnings. The news report’s 1-year target of $260-$270 is realistic on this horizon.
  • 6-Month Target (Optimistic): $270 - $275
    • Rationale: This scenario factors in a successful resolution of the DePuy Synthes sale, providing a significant cash infusion and multiple expansion, combined with continued strong performance from the high-growth neuroscience and immunology segments. It also assumes a breakout to new highs.

Action Strategy

Strategy Summary

Recommendation: BUY Rationale: The combination of a robust, high-margin pharmaceutical pipeline successfully navigating the Stelara patent cliff, a defensive dividend aristocrat status in a possibly volatile market, and a technically sound bullish chart structure outweighs the known, priced-in risks of litigation and valuation. The potential value unlock from a DePuy Synthes sale provides an optionality kicker.

Strategic Actions:

  1. Entry Strategy: Do not chase the current price. Use a scaling-in approach. Place a limit buy order at $242, just above the 20-day MA and Bollinger middle band support. If filled, this provides a better risk/reward entry. If the stock pulls back further, consider a second tranche near $235, close to the lower Bollinger Band.
  2. Position Sizing: Given the historical 50% stop-loss rate, keep the position size moderate. Allocate capital accordingly within your portfolio’s risk parameters.
  3. Stop-Loss: A hard stop-loss at $230 is essential. This is below the significant 60-day MA support ($222.95) and the major $235 support level. It follows the historical insight that the average MAE for failed trades was around -3%; this stop represents a ~6% risk from a $245 entry, which is prudent for this stock’s profile.
  4. Profit-Taking: Take a disciplined, partial profit-taking approach.
    • Sell 1/3 of position at $255 (near the 52-week high/resistance)
    • Sell another 1/3 at $260 (upper end of fundamental target)
    • Let the final 1/3 run with a trailing stop towards the optimistic target, reevaluating based on new data as it approaches.

The core of this trade is patience. Wait for the right entry point, manage risk aggressively with the stop-loss, and take profits methodically as key resistance levels are reached. The fundamental growth story here is strong enough to warrant a position.

AI Bull vs AI Bear
Round-by-round arguments

Round 1 - Bear case

  • JNJ's valuation is unsustainable, trading at a forward P/E over 20 and P/S of 27 after recent large gains. The technical analysis indicates major resistance and profit-taking risk. The patent cliff for blockbuster Stelara presents certain, imminent revenue loss, while new pipeline drugs are speculative. Persistent talc litigation is an unquantifiable liability, not priced in. A high debt-to-equity ratio of nearly 60% is a headwind with higher interest rates. The dividend yield is unattractive at the current elevated price.

Detail Preview

Right, let's get straight to the point. While the bullish analyst is busy polishing JNJ's Dividend Aristocrat trophy and celebrating pipeline news, they're completely ignoring the massive red flags waving right in front of them. This stock is a classic case of "priced to perfection" with significant underlying risks that make it a terrible investment at current levels. Let's break down exactly why you should be selli…

Round 2 - Bear case

  • JNJ's forward P/E of 20.43 is historically elevated. Technicals suggest a pullback: MACD is negative, RSI nears overbought, and 69% of positions are profitable, creating resistance. The Stelara patent cliff will create a $10B+ revenue gap not yet replaced by new drugs. Persistent litigation and a 59.67% debt-to-equity ratio create recurring risk and rising costs. A potential DePuy divestiture introduces execution risk. The stock's 54.7% run-up is unsustainable.

Detail Preview

(Adjusting my tie and leaning forward with a skeptical expression) Alright, let's cut through the bullish optimism here. While my colleague highlights JNJ's apparent strengths, I see significant vulnerabilities that make this stock a dangerous investment at current levels. First, let's address this "reasonable" forward P/E of 20.43. This isn't reasonable - it's historically elevated for JNJ and represents a premium v…

Round 1 - Bull case

  • JNJ's forward P/E of 20.43 is reasonable for a Dividend Aristocrat and aligns with the healthcare sector average. Growth is underpinned by strong immunology and neuroscience portfolios, replacing Stelara revenue. The chart shows bullish alignment, and recent consolidation is healthy. Litigation is a priced-in, manageable liability. The debt-to-equity ratio is standard, with strong liquidity and profitability. The dividend growth story remains compelling, and a potential DePuy Synthes sale could unlock value.

Detail Preview

(Leaning forward, adopting a confident but measured tone) Let's address these bearish concerns head-on, because I believe you're missing the forest for the trees here. JNJ isn't some speculative biotech startup—it's a healthcare fortress with multiple growth engines firing simultaneously. On valuation: Yes, JNJ has appreciated significantly, but calling a forward P/E of 20.43 "unsustainable" for a company of this qua…

Round 2 - Bull case

  • Forward P/E of 20.43 is a reasonable premium for accelerated growth from neuroscience and immunology. Products like Spravato are already replacing Stelara revenue. Technically, MACD is positive and moving averages are bullish. The market has priced in talc liabilities, and JNJ's debt-to-equity ratio is conservative for its sector. A potential DePuy Synthes sale is value creation, not risk. The stock's run-up is a fundamental reassessment of its successful transformation.

Detail Preview

(Leaning forward, placing both hands on the table with conviction) Let's address these concerns head-on, because when you actually break down the numbers and look at JNJ's strategic position, the bullish case becomes compelling. First, on valuation: A forward P/E of 20.43 isn't "historically elevated" – it's reasonable premium for a company with JNJ's quality. You're comparing today's forward multiple to historical t…

Round 1 - Bear case

  • JNJ's valuation is unsustainable, trading at a forward P/E over 20 and P/S of 27 after recent large gains. The technical analysis indicates major resistance and profit-taking risk. The patent cliff for blockbuster Stelara presents certain, imminent revenue loss, while new pipeline drugs are speculative. Persistent talc litigation is an unquantifiable liability, not priced in. A high debt-to-equity ratio of nearly 60% is a headwind with higher interest rates. The dividend yield is unattractive at the current elevated price.

Detail Preview

Right, let's get straight to the point. While the bullish analyst is busy polishing JNJ's Dividend Aristocrat trophy and celebrating pipeline news, they're completely ignoring the massive red flags waving right in front of them. This stock is a classic case of "priced to perfection" with significant underlying risks that make it a terrible investment at current levels. Let's break down exactly why you should be selli…

Round 1 - Bull case

  • JNJ's forward P/E of 20.43 is reasonable for a Dividend Aristocrat and aligns with the healthcare sector average. Growth is underpinned by strong immunology and neuroscience portfolios, replacing Stelara revenue. The chart shows bullish alignment, and recent consolidation is healthy. Litigation is a priced-in, manageable liability. The debt-to-equity ratio is standard, with strong liquidity and profitability. The dividend growth story remains compelling, and a potential DePuy Synthes sale could unlock value.

Detail Preview

(Leaning forward, adopting a confident but measured tone) Let's address these bearish concerns head-on, because I believe you're missing the forest for the trees here. JNJ isn't some speculative biotech startup—it's a healthcare fortress with multiple growth engines firing simultaneously. On valuation: Yes, JNJ has appreciated significantly, but calling a forward P/E of 20.43 "unsustainable" for a company of this qua…

Round 2 - Bear case

  • JNJ's forward P/E of 20.43 is historically elevated. Technicals suggest a pullback: MACD is negative, RSI nears overbought, and 69% of positions are profitable, creating resistance. The Stelara patent cliff will create a $10B+ revenue gap not yet replaced by new drugs. Persistent litigation and a 59.67% debt-to-equity ratio create recurring risk and rising costs. A potential DePuy divestiture introduces execution risk. The stock's 54.7% run-up is unsustainable.

Detail Preview

(Adjusting my tie and leaning forward with a skeptical expression) Alright, let's cut through the bullish optimism here. While my colleague highlights JNJ's apparent strengths, I see significant vulnerabilities that make this stock a dangerous investment at current levels. First, let's address this "reasonable" forward P/E of 20.43. This isn't reasonable - it's historically elevated for JNJ and represents a premium v…

Round 2 - Bull case

  • Forward P/E of 20.43 is a reasonable premium for accelerated growth from neuroscience and immunology. Products like Spravato are already replacing Stelara revenue. Technically, MACD is positive and moving averages are bullish. The market has priced in talc liabilities, and JNJ's debt-to-equity ratio is conservative for its sector. A potential DePuy Synthes sale is value creation, not risk. The stock's run-up is a fundamental reassessment of its successful transformation.

Detail Preview

(Leaning forward, placing both hands on the table with conviction) Let's address these concerns head-on, because when you actually break down the numbers and look at JNJ's strategic position, the bullish case becomes compelling. First, on valuation: A forward P/E of 20.43 isn't "historically elevated" – it's reasonable premium for a company with JNJ's quality. You're comparing today's forward multiple to historical t…

End of debate